VarmX and Rentschler Biopharma expand collaboration from early development to late‑stage and commercial manufacturing of VMX-C001 VMX‑C001 builds on strong...
Japanese regulator, the PMDA, waived the requirement for a Phase 1 trial in Japanese subjects for lead asset VMX-C001, enabling...
Oral and poster presentations on key VMX-001 data in San Diego from 7-10 December Leiden, The Netherlands, 3 December 2024...
Leadership team fully strengthened to drive next phase of development Leiden, The Netherlands, 12 november 2024 VarmX, a biotech company...
Leiden, The Netherlands, 10 september 2024 VarmX, a biotech company focusing on the development of innovative approaches for the reversal...
Leiden, The Netherlands, 26 June 2024 VarmX, a biotech company focusing on the development of innovative approaches for the reversal...
Factor Xa direct oral anticoagulants (Fxa-DOACs) require rapid reversal in patients with serious bleeding or prior to urgent surgery.
...